Jun. 16 at 8:39 PM
$ABVX Attached below is a somewhat lengthy AI analysis of TGuggenheim's write-up. Interesting read. I'm you more intelligent types already are aware of the below key data points. Best to all....
Guggenheim naming Abivax as its top biotech pick ahead of the Phase III ABTECT Maintenance Part Two readout tells you one thing:
They believe the malignancy signal will fall within acceptable epidemiologic benchmarks.
Their entire thesis hinges on whether obefazimod’s cancer incidence aligns with known background rates in refractory UC.
The Benchmarks Guggenheim Cares About
They specifically cite two epidemiologic reference ranges for ulcerative colitis patients:
1. Non melanoma skin cancer (NMSC)
Expected background: 0.7–1.4 per 100 patient years
2. Non NMSC malignancies
Expected background: 0.3–0.7 per 100 patient years
These ranges come from large UC cohorts treated with biologics, immunomodulators, or multiple prior therapies. They represent real world baseline risk, not placebo controlled trial risk.
If obefazimod’s exposure adjusted incidence rates (EAIRs) fall within or below these ranges, the malignancy imbalance becomes:
• Statistically explainable
• Clinically manageable
• Label worthy but not boxed warning worthy
This is exactly what Guggenheim is betting on
Why This Matters:
The FDA does not look at raw malignancy counts. They look at EAIRs — cancers per 100 patient years — because:
• UC patients are older
• Many have prior immunosuppressant exposure
• Cancer risk increases with disease duration
• Skin cancer risk increases with age and prior therapies
If obefazimod’s EAIRs normalize after adjustment, the malignancy “signal” becomes noise, not a regulatory crisis.
What to Watch in the Late June Readout
Guggenheim expects Abivax to release three critical datasets:
1. Preliminary safety data (raw counts)
This is what caused the initial selloff.
2. Exposure adjusted incidence rates (EAIRs)
This is the real safety signal. If EAIRs fall inside the UC benchmarks above → bullish.
3. Maintenance efficacy results
If efficacy remains strong (as in Part One), it reinforces the risk/benefit profile.
What Would Be Bullish
• NMSC EAIR ≤1.4 per 100 PY
• Non NMSC EAIR ≤0.7 per 100 PY
• No clustering in a single cancer type
• No dose response trend (25 mg vs 50 mg)
• No time to event acceleration
• No mechanistic plausibility for carcinogenesis
If these hold, the malignancy imbalance becomes non actionable from an FDA standpoint.
What Would Be Bearish
• EAIRs above UC background
• Multiple cancers of the same type
• Events occurring early after drug initiation
• Clear dose response (more cancers at 50 mg)
• Younger patients affected (not age driven)
• Events in patients without prior cancer risk factors
This is the scenario that raises boxed warning discussions.
Timing
Guggenheim expects the Part Two maintenance data in late June, including:
• EAIRs
• Subtype breakdown
• Age adjusted analysis
• Prior therapy stratification
• Updated efficacy
***This is the single most important ABVX catalyst of 2026***
